Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784991 · ClinicalTrials.gov registry record · NA
Study of Respiratory Depression When Using a Hydromorphone Pain Protocol
A NA study, sponsored by Albert Einstein Healthcare Network.
- Terminated
- Registry status
- NA
- Development phase
- 116
- Enrollment target
NCT01784991: Clinical Trial NA study, sponsored by Albert Einstein Healthcare Network.
NCT01784991 is a NA study that was terminated before completion, run by Albert Einstein Healthcare Network. The registered enrollment target is 116 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01784991, a NA study, was terminated before completion, sponsored by Albert Einstein Healthcare Network.
- TERMINATED
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
Study Summary
This is a study about the efficiency and safety of a 1mg+1mg hydromorphone pain management protocol for the treatment of moderate to sever pain in the Emergency Department. Appropriate patients 60 years and older who present with a condition that causes moderate to severe pain, according to the attending physician's judgment, in which the physician would order the use of parenteral analgesia will be enrolled in one of two study arms, "1+1" versus usual care group. 1+1 patients will receive 1mg hydromorphone followed by another 1mg after 15 minutes if pain persists. Usual care group patients will have pain treated per the discretion of the attending physician. Respiratory status, vital signs, and pain scores will be monitor to assess the efficiency of pain control as well as the safety of pain medicine administration in terms of respiratory depression.
Primary Outcome
Incidence of respiratory depression (defined as a ETCO2 of 50 mmHg or greater, a 10% change from baseline, or loss of waveform for 15 seconds or greater)
Interventions
- DRUG Hydromorphone
- DRUG Usual care group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-04-16 |
| Phase | NA |
Why NCT01784991 stopped before completion
NCT01784991 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Hydromorphone is the first listed.
NCT01784991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01784991 about?
NCT01784991 is a clinical study titled "Study of Respiratory Depression When Using a Hydromorphone Pain Protocol". This is a study about the efficiency and safety of a 1mg+1mg hydromorphone pain management protocol for the treatment of moderate to sever pain in the Emergency Department. Appropriate patients 60 years and older who present with a condition that causes moderate to severe pain, according to the atte...
What is the current status of trial NCT01784991?
This trial is currently terminated. It is a NA study. The enrollment target is 116 participants. The study started on 2011-12. Estimated completion is 2014-04-16.
What interventions are being tested in trial NCT01784991?
The interventions under investigation include: Hydromorphone (DRUG), Usual care group (DRUG).
Who is sponsoring clinical trial NCT01784991?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01784991's enrollment target sits among peer trials
116 808th of 2000 higher than 1,191 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia